OSI Confident On Tarceva After Iressa Approval; Brain Cancer Is Back-Up Plan
OSI Pharmaceuticals is confident about Tarceva's prospects for FDA clearance based on the recent Subpart H approval of AstraZeneca's Iressa
OSI Pharmaceuticals is confident about Tarceva's prospects for FDA clearance based on the recent Subpart H approval of AstraZeneca's Iressa